Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin or Galantamine for Negative Symptoms and Cognition in Schizophrenia
NCT01012167Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Feb 2010
- Primary completion
- Jul 2014
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of oxytocin nasal spray, galantamine in schizophrenia, sponsored by University of Maryland, Baltimore. Started Feb 2010; status: completed.
02
Drugs
oxytocin nasal spraygalantamine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01012167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01012167.